Hear how past DES lessons and today’s newest tech are shaping Medtronic’s future coronary strategy

MedtronicTalks

Innehåll tillhandahållet av MedtronicTalks and Tom Salemi. Allt poddinnehåll inklusive avsnitt, grafik och podcastbeskrivningar laddas upp och tillhandahålls direkt av MedtronicTalks and Tom Salemi eller deras podcastplattformspartner. Om du tror att någon använder ditt upphovsrättsskyddade verk utan din tillåtelse kan du följa processen som beskrivs här https://sv.player.fm/legal.

2y ago 36:53

MP3•Episod hem

Fetch error

Hmmm there seems to be a problem fetching this series right now. Last successful fetch was on October 10, 2024 22:11 (18d ago)

What now? This series will be checked again in the next day. If you believe it should be working, please verify the publisher's feed link below is valid and includes actual episode links. You can contact support to request the feed be immediately fetched.

In this episode, Jason Fontana, vice president coronary and renal denervation marketing and strategy at Medtronic, will walk us through Medtronic’s successful entry into the drug-eluting stent market over a decade ago with the Endeavor DES, the first modular drug-eluting stent. With a focus on healing and deliverability, Medtronic overcome a late-start to become a leader of the pack following the approval of the Resolute Integrity DES. We’ll review Medtronic’s current coronary portfolio including Onyx Frontier DES with a dual flex balloon. Fontana will also explain how new technologies and diagnostic techniques will help it set the pace in the coronary space in the future. Thanks to Delve for sponsoring! Thank you for listening to the MedtronicTalks Podcast.

47 episoder

#Tech #MedtronicTalks #Tom Salemi